Innate Pharma S.A. (NASDAQ: IPHA) Stock Information | RedChip
Image

ASK REDCHAT® ANYTHING ABOUT INNATE PHARMA S.A.

Innate Pharma S.A. (NASDAQ: IPHA)
Listen to this Section


$1.95
+0.2300 ( -0.51% ) 66.8K

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Market Data


Open $1.95
Previous Close $1.72
Volume 66.8K
Market Cap $165.95M
Day Range $1.74 - $2.05
52 Week Range $1.29 - $3.51
Shares Outstanding 83.81M
Change % -0.51%
Net Change ▲ 0.2300
Insider Ownership N/A
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology: Pharmaceutical Preparations
IPO Year 2015
Country France
Under Writer IPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: 0.00

Date Type Amount Purchased Purchaser
No records found.

Institutional Ownership

Total Market Value $ 0.00

Symbol Issuer Name Market Value ↓ Share Quantity
No records found.

SEC Fillings


Form Type Description Pages Date
6-k Form 6-K 2 Jan 21, 2025
6-k Form 6-K 2 Jan 16, 2025
6-k Form 6-K 2 Jan 10, 2025
6-k Form 6-K 2 Dec 20, 2024
6-k Form 6-K 2 Dec 09, 2024
6-k Form 6-K 3 Dec 06, 2024
6-k Form 6-K 2 Dec 03, 2024
6-k Form 6-K 2 Nov 20, 2024
6-k Form 6-K 2 Nov 19, 2024
6-k Form 6-K 2 Nov 13, 2024

Latest News


× Before browsing our site, please accept our cookies policy